The abstract is read at the publisher; the summary is JClub's.
Adjuvant pegylated-interferon alfa-2a after nucleos(t)ide withdrawal increases 3-year HBsAg loss from 3% to 14% in non-cirrhotic HBeAg-negative chronic HBV.
- Why it matters: NA withdrawal yields HBsAg loss in only 5%–20% over 3 years, leaving many patients without a durable finite response; adding PEG-IFN may improve outcomes.
- What they did: In the randomized multicenter NUC-B trial, non-cirrhotic HBeAg-negative patients on NA were assigned to withdrawal alone or withdrawal plus 16 weeks of PEG-IFNα 180 μg weekly starting 4 weeks later.
- The result: At 3 years, HBsAg loss was higher with PEG-IFNα (OR 5.39; 95% CI 1.11–26.19; p=0.037), with fewer exaggerated flares (13.4% vs 27.9%) and similar NA return (28.4% vs 34.9%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.